Table 4

Changing Disease Course of Crimean-Congo Hemorrhagic Fever in Children, Turkey

Pembe Derin Oygar¹, Sibel Laçinel Gürlevik, Erdal Sağ, Sare İlbay, Tekin Aksu, Osman Oğuz Demir, Yasemin Coşgun, Selin Aytaç Eyüpoğlu, Jale Karakaya, Şule Ünal Cangül, Ali Bülent Cengiz, and Yasemin Özsürekci

Author affiliations: Hacettepe University, Ankara, Turkey (P.D. Oygar, S.L. Gürlevik, E. Sağ, T. Aksu, O.O. Demir, S.A. Eyüpoğlu, J. Karakaya, Ş.Ü. Cangül, A.B. Cengiz, Y. Özsürekci); İhsan Doğramacı Children’s Hospital, Ankara (P.D. Oygar, S.L. Gürlevik, T. Aksu, O.O. Demir, S.A. Eyüpoğlu, Ş.Ü. Cangül, A.B. Cengiz, Y. Özsürekci); Ankara Training and Research Hospital, Ankara (E. Sağ); Hacettepe University Rheumatology Translational Medicine Laboratories, Ankara (S. İlbay); General Directorate of Public Health, Ministry of Health, Microbiology Reference and Biological Materials Laboratory, Ankara (Y. Coşgun)

Main Article

Variations in correlation of laboratory parameters with cytokines/chemokines for 12 pediatric case-patients with Crimean-Congo hemorrhagic fever, based on time interval, Turkey*†

Cytokine/chemokine	Neutrophil count	Platelet count	Fibrinogen	D-dimer	a-PTT	INR	Ferritin	LDH	ALT	TG
IFN-α	NA	NA	r2 = 0.726; p2 = 0.027	NA	NA	r1 = 0.720; p1 = 0.029	NA	NA	NA	r2 = 0.840; p2 = 0.018
IFN-γ	NA	NA	r2 = 0.770; p2 = 0.015	NA	NA	NA	r1 = 0.0857; p1 = 0.007	NA	NA	r2 = 0.863; p2 = 0.012
CXCL10	NA	NA	NA	r3 = 0.669; p3 = 0.049	r2 = 0.677; p2 = 0.045	NA	NA	NA	NA	r1 = −0.920; p1 = 0.009
CXCL11	NA	NA	NA	NA	NA	NA	NA	r3 = −0.716; p3 = 0.046	NA	r1 = −0.851; p1 = 0.032
MIP-3α	r1 = −0.783; p1 = 0.013	NA	NA	NA	NA	NA	r1 = 0.771; p1 = 0.025	r1 = 0.667; p1 = 0.05	NA	NA
IL-1β	NA	NA	NA	NA	NA	NA	NA	NA	NA	r2 = 0.883; p2 = 0.009
lL-10	NA	r3 = −0.748; p3 = 0.021	NA	NA	NA	NA	NA	NA	NA	r2 = 0.870; p2 = 0.011
IL-18	r1 = −0.721; p1 = 0.029	r1 = −0.762; p1 = 0.017;	r1 = −0.676; p1 = 0.046; r2 = 0.693; p2 = 0.038	NA	NA	NA	NA	r1 = 0.670; p1 = 0.048	r2 = 0.688; p2 = 0.049	NA
IL-33	NA	NA	r2 = 0.943; p2 = 0.001	NA	NA	NA	NA	NA	r2 = 0.739; p2 = 0.023	r2 = 0.851; p2 = 0.015
CCL17	NA	r1 = 0.823; p1 = 0.006; r2 = 0.851; p2 = 0.004	NA	NA	r1 = −0.733; p1 = 0.025	NA	NA	r3 = −0.907; p3 = 0.002	NA	NA
CCL11	NA	NA	NA	r2 = −0.758; p2 = 0.018; r3 = −0.668; p3 = 0.049	NA	NA	r2 = −0.681; p2 = 0.043	r2 = −0.669; p2 = 0.049; r3 = −0.895; p3 = 0.003	NA	NA
ENA78	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

*First time interval, 68–72 h after baseline; second, 120–132 h; third, 156–180 h. CCL, CC chemokine ligand; CXCL, C-X-C motif chemokine ligand; ENA, epithelial neutrophil-activating; IL, interleukin; IFN, interferon; IP, IFN-γ-inducible protein; I-TAC, interferon-inducible T-cell alpha chemoattractant; RANTES, regulated upon activation, normal t cell expressed and presumably secreted; MIP, macrophage inflammatory proteins; NA, not applicable; TARC, hymus- and activation-regulated chemokine. †r1, correlation coefficient during the first time interval; p1, asymptotic significance (2-tailed) during the first time interval; r2, correlation coefficient during the second time interval; p2, asymptotic significance (2-tailed) during the second time interval; r3, correlation coefficient during the third time interval: p3, asymptotic significance (2-tailed) during the third time interval.

Main Article

¹Current affiliation: Nicosia State Hospital, Burhan Nalbantoglu General Hospital, Nicosia, Cyprus.

Page created: December 07, 2022

Page updated: January 21, 2023

Page reviewed: January 21, 2023

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

Volume 29, Number 2—February 2023

Synopsis

Changing Disease Course of Crimean-Congo Hemorrhagic Fever in Children, Turkey

Table 4